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Background: For the primary prevention of sudden cardiac death, guidelines provide left ventricular ejection
fraction (EF) criteria for implantable cardioverter defibrillator (ICD) placement without specifying the technique by
which it should be measured. We sought to investigate the potential impact of performing cardiovascular magnetic
resonance (CMR) for EF on ICD eligibility.
Methods: The study population consisted of patients being considered for ICD implantation who were referred for
EF assessment by CMR. Patients who underwent CMR within 30 days of echocardiography were included.
Echocardiographic EF was determined by Simpson’s biplane method and CMR EF was measured by Simpson’s
summation of discs method.
Results: Fifty-two patients (age 62±15 years, 81% male) had a mean EF of 38 ± 14% by echocardiography and
35 ± 14% by CMR. CMR had greater reproducibility than echocardiography for both intra-observer (ICC, 0.98 vs 0.94)
and inter-observer comparisons (ICC 0.99 vs 0.93). The limits of agreement comparing CMR and echocardiographic
EF were – 16 to +10 percentage points. CMR resulted in 11 of 52 (21%) and 5 of 52 (10%) of patients being
reclassified regarding ICD eligibility at the EF thresholds of 35 and 30% respectively. Among patients with an
echocardiographic EF of between 25 and 40%, 9 of 22 (41%) were reclassified by CMR at either the 35 or 30%
threshold. Echocardiography identified only 1 of the 6 patients with left ventricular thrombus noted incidentally
on CMR.
Conclusions: CMR resulted in 21% of patients being reclassified regarding ICD eligibility when strict EF criteria were
used. In addition, CMR detected unexpected left ventricular thrombus in almost 10% of patients. Our findings
suggest that the use of CMR for EF assessment may have a substantial impact on management in patients being
considered for ICD implantation.
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Implantable cardioverter defibrillator (ICD) placement
has been shown to reduce the risk of sudden cardiac
death in patients with severe left ventricular dysfunc-
tion [1-3]. Guidelines recommend ICD implantation for
primary prevention in patients with left ventricular
ejection fraction (EF) below 30% or 35% depending on
etiology and symptoms [1-3]. EF is the best validated
of the predictors of sudden death and is the main vari-
able used in clinical practice to make treatment deci-
sions about ICD eligibility. While specific EF criteria
are suggested, the technique by which EF should be
measured is not specified in the guidelines [1-3]. In
clinical practice, echocardiography is the modality most
commonly used to assess left ventricular function and
was one of several modalities used in trials establishing
the efficacy of ICD therapy [4-6]. However, cardiovas-
cular magnetic resonance (CMR) is now considered
the gold standard for EF measurement and is known
to have greater reproducibility than echocardiography
[7-9]. When strict EF thresholds are used for primary pre-
vention ICD placement, it is unknown whether differences
between modalities would alter clinical decisions. We
sought to investigate the potential clinical impact of
performing CMR for EF in patients being evaluated
for ICD therapy.
Methods
The study population consisted of patients being consid-
ered for ICD implantation at two academic medical cen-
tres between March 20, 2007 and Nov 19, 2010. Patients
referred for CMR with the indications of both “ICD” and
“EF” assessment were identified from a database. All
patients who had undergone CMR within 30 days of
echocardiography were included in the study. No
patients were excluded based on image quality, to reflect
a “real world” population of patients. Two patients were
in atrial fibrillation, and both were well rate-controlled
resulting in satisfactory image quality for both echocar-
diographic and CMR examinations. Patients undergoing
coronary revascularization or cardiac resynchronization
therapy between echocardiography and CMR examina-
tions were excluded. Clinical records were reviewed to
identify risk factors and co-morbid clinical conditions.
Ischemic heart disease was determined to be the cause
of left ventricular dysfunction based on a history of myo-
cardial infarction, coronary revascularisation or a sten-
osis of greater than 70% severity in at least one major
epicardial coronary artery. Approval was obtained from
the institutional research ethics boards.
Echocardiography
A commercially available clinical system (IE 33, Philips
Healthcare Canada) was used to perform standard clin-
ical two-dimensional echocardiography. All studiesincluded focused imaging of the left ventricle in the ap-
ical two and four chamber views for EF assessment.
Echocardiographic studies were read by expert obser-
vers (H.L.P., M.H.) on commercially available software
(Xcelera, Philips Healthcare Canada). Observers per-
formed their analyses independent of one another and
were blinded to CMR results. All studies were read a
second time in random order after a 4 week interval. EF
was measured by Simpson’s biplane method by manual
tracing of endocardial borders on apical 2 and 4 cham-
ber images according to American Society of Echocardi-
ography Guidelines [10]. A qualitative assessment was
also made regarding the pattern of left ventricular dys-
function; marked variability in function from one seg-
ment to another suggestive of an ischemic cause was
considered a regional pattern, while a uniform pattern of
left ventricular dysfunction was deemed global. The
presence or absence of thrombus was assessed using all
images available in the echocardiographic study. Echo-
cardiographic contrast agent for left ventricular opacifi-
cation was not used.
Cardiovascular Magnetic Resonance (CMR)
CMR was performed on one of two commercially avail-
able 1.5 Telsa field strength systems (Achieva, Philips
Medical Systems, Best, Netherlands and Signa Excite,
GE Medical Systems Milwaukee, WI). A standard clin-
ical CMR was performed including a segmented k-space
cine steady state free precession (SSFP) series in a left
ventricular short axis orientation. Slice thickness was 8 mm
with no gap and the in-plane resolution was approxi-
mately 1.6 x 1.6 mm. There were 20 – 25 phases per
cardiac cycle resulting in a temporal resolution of <50
ms. Late gadolinium enhancement images were acquired
approximately 10 minutes after intravenous adminis-
tration of 0.1-0.2 mmol/kg of gadolinium (gadobutrol
or gadopentate dimeglumine) with the inversion time
adjusted to optimally null the normal myocardium [11].
CMR images were analyzed by experienced readers
(L.J., S.J.), blinded to the other’s results, on a single
commercially available platform (CMR42, Circle Car-
diovascular Imaging, Calgary, Canada). EF was mea-
sured by manual planimetry of the left ventricular
endocardium in short axis cine images at end-systole
and end-diastole. End-diastolic and end-systolic phases
were chosen independently by each observer based on
maximum and minimum volume, with multiple phases
contoured in case of doubt. At the basal slice, the ven-
tricular cavity was differentiated from the atrium by
the presence of ventricular myocardium and was con-
firmed on a co-registered long-axis image. Papillary
muscles were excluded from the left ventricular mass,
that is, they were ignored and included in the left ven-
tricular cavity volume. Both cine SSFP and late
Table 1 Characteristics of Study Population
n = 52
Age (years) ± SD 62 ± 15
Male Gender 42 (81%)
Ischemic Heart Disease 20 (38%)
Hypertension 21 (40%)
Diabetes mellitus 13 (25%)
Dyslipidemia 37 (78%)
EF by CMR 35 ± 14%
EF by echocardiography 38 ± 14%
LV end-diastolic volume by echocardiography (mL) 165 ± 83
LV end-systolic volume by echocardiography (mL) 111 ± 75
LV end-diastolic volume by CMR (mL) 238 ± 98
LV end-systolic volume by CMR (mL) 166 ± 97
Interval between echocardiography and CMR 3 days (IQR 1 – 9)
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for left ventricular thrombus. The diagnosis of
thrombus was made based upon the identification of
low signal intensity filling defects within the left ven-
tricular cavity adjacent to myocardium with severely
impaired function [12,13]. Thrombus was distinguished
from microvascular obstruction related to infarction by
its location within the left ventricular cavity (as
opposed to the myocardium) and its stability of size on
consecutive late enhancement images [14]. In case of
disagreement another expert reader independently adju-
dicated the results (K.C., A.Y.).Statistical analysis
Statistical analyses were performed on Stata version 10
(Statacorp, College Station, Texas, USA) and MedCalc
version 11.6.1.0 (MedCalc Software, Mariakerke, Bel-
gium). Continuous variables were expressed as means
and standard deviations, or medians and inter-quartile
ranges (IQR) for data that were not normally distributed.Figure 1 Bland Altman plots for interobserver variability. a, Echocardio
Resonance Ejection Fraction (CMR EF), with limits of agreement.Methods of EF assessment were compared using Bland-
Altman analysis, Student’s paired t-test and Pearson’s
correlation coefficient. Reproducibility was also assessed
using the intra-class correlation coefficient (ICC). The
Kappa statistic was used to assess agreement between
echocardiography and CMR classification, and logistic
regression was used to determine univariate predictors
of misclassification. A p value of 0.05 was regarded as
statistically significant.
Results
Fifty-two (52) patients were identified. The mean age
was 62 +/− 15 years and 42 (81%) were male. There was
a median of 3 days (interquartile range 1–9) between
echocardiographic and CMR studies. (Table 1) CMR was
found to have greater reproducibility than echocardiog-
raphy for both intra-observer (ICC 0.98 vs 0.94) and
inter-observer comparisons (ICC 0.99 vs 0.93). The lim-
its of agreement were also substantially narrower for
CMR as compared with echocardiography (Figure 1)
(Table 2). Using CMR as the reference standard, echo-
cardiography was found to systematically overestimate
EF by an average of 3 percentage points (37.5% vs 34.4%,
p = 0.001). More importantly, the random error between
echocardiography and CMR was substantial, as evi-
denced as by the limits of agreement (−15.5, 9.5) when
comparing techniques (Figure 2). There was no relation-
ship between the time interval between echocardiog-
raphy and CMR and the absolute difference in EF
between the two techniques (r = −0.03, p = 0.85).
At the EF threshold of 35%, CMR reclassified 11 of
52 (21%) of patients with respect to eligibility for ICD.
In 10 of the 11 instances of reclassification, CMR
found the EF to be below 35% making the patient po-
tentially ICD-eligible (Table 3). At the EF threshold of
30%, CMR reclassified 5 patients (9.6%) and in all 5
instances determined the patient was ICD-eligible when
echocardiography suggested otherwise (Table 4). When
the echocardiographic EF was between 25 – 40%, 9 ofgraphic Ejection Fraction (Echo EF) and b, Cardiac Magnetic
Table 2 Reproducibility of CMR and Echocardiographic EF
CMR Echocardiography
Intraobserver Interobserver Intraobserver Interobserver
ICC (95% CI) 0.98 (0.96 – 0.99) 0.99 (0.98 – 0.99) 0.94 (0.90 – 0.97) 0.93 (0.88 – 0.96)
Pearson’s Correlation Coefficient 0.98 0.98 0.90 0.90
Bland-Altman Bias 1.63 −1.1 1.8 −1.7
Limits of Agreement −5.3, 8.5 −7.0, 4.7 −10.6, 14.3 −13.7, 10.3
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or 35% EF threshold. On univariate analysis, the only
significant predictor of reclassification was an echocar-
diographic EF within 5 percentage points of the com-
monly used thresholds (Table 5).
Left ventricular thrombus was identified in one patient
by echocardiography and in five additional patients by
CMR. The prevalence of unexpected left ventricular
thrombus identified by CMR was therefore 9.6%
(Figure 3).
Discussion
Patient selection for ICD implantation is one of the few
clinical scenarios in which a precise EF threshold is used.
In this study, we found that up to 21% of patients would
have been reclassified by CMR regarding ICD eligibility
based on EF criteria. Moreover, in those with an echo-
cardiographic EF within 5 percentage points of the com-
monly used thresholds of 30 or 35%, CMR reclassified
41% of patients, and usually in favour of ICD implant-
ation. Given the clinical importance of ICDs and their
expense, the potential impact of CMR in this patient
group is substantial.
Several studies have examined EF derived from differ-
ent imaging modalities in patients being considered for
ICD implantation [15-19]. Radionucleotide ventriculo-
graphy, although not used in this study, is a modality
frequently used in patients being considered for ICD im-
plantation [17]. When available however, CMR remains
the technique of choice, not only because of it’s greater
reproducibility, but because it spares the patientFigure 2 Comparison of CMR and echocardiographic Ejection Fractionsignificant radiation exposure and may provide other
useful information in heart failure patients [20].
Our findings regarding CMR and echocardiographic
EF are in keeping with prior research. CMR has been
shown to have less intra and inter-observer variability
than echocardiography, and its higher inter-study re-
producibility makes it the modality of choice for
detecting changes in EF over time [7,9]. The systematic
bias between CMR and echocardiographic EF has been
variable in published research. [7-9,21,22]. This discrep-
ancy most likely reflects differences in local practice
regarding echocardiographic EF measurement and dif-
ferent conventions for CMR EF quantification. For ex-
ample, in this study papillary muscles were excluded
from the left ventricular mass by CMR, a convention
that leads to a lower CMR ejection fraction than when
papillary muscles are traced and included in the left
ventricular myocardial mass [23,24]. On echocardiog-
raphy, papillary muscles are excluded from the left ven-
tricular mass when measuring Simpson’s biplane EF
and therefore the same methodology - the standard in
the participating institutions - was employed for CMR.
The systematic bias between echocardiographic and
CMR EF in this study is however eclipsed by the large
random error when comparing techniques. Potential
sources of discrepancy between echocardiography and
CMR EF were examined in our cohort of patients
(Table 5). Although Simpson’s biplane method has lim-
itations in geometrically distorted ventricles, neither a
regional pattern of left ventricular dysfunction nor is-
chemic etiology were predictors of reclassification for. a, Bland-Altman plot and b, Scatterplot.
Table 3 ICD Eligibility at EF 35% Threshold
Echocardiographic EF
> = 35% < 35%
CMR EF >= 35% 21 1
< 35% 10 20
Kappa = 0.59.
Table 5 Predictors of Reclassification of ICD Eligibility by
CMR
Variable Odds Ratio p value
Days between
echocardiography and CMR
0.94 (0.84 – 1.09) 0.30
History of Ischemic Heart Disease 0.64 (0.17 – 2.39) 0.51
Left bundle branch block
on electrocardiogram
1.15 (0.26 – 5.16) 0.86
Apical Aneurysm
(echocardiography)
0.26 (0.03 – 2.31) 0.23
Regional pattern of
left ventricular dysfunction
1.17 (0.32 – 4.26) 0.82
Echocardiographic EF 25 – 40% 6.23 (1.44 – 26.95) 0.01
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bundle branch block, as a surrogate for dyssynchrony,
was not found to a predictor. While our study was
underpowered for this purpose, it is likely that the in-
fluence of any of these factors would be overshadowed
by the proximity of the echocardiographic EF to the
ICD eligibility threshold. That is, regardless of other
characteristics, patients with echocardiographic EFs
close to 30 or 35% are the ones most likely to fall on
the other side of the threshold after CMR.
In our cohort of 52 patients, standard 2-dimensional
echocardiography identified only 1 of the 6 patients
with left ventricular thrombi seen on CMR. These find-
ings are in keeping with the known low sensitivity of
echocardiography for left ventricular thrombus detec-
tion [13]. Use of echocardiographic contrast agent is
known to improve the sensitivity of echocardiography,
although layered mural thrombi would be difficult to
detect even with contrast [14]. In a general heart fail-
ure population, the identification of left ventricular
thrombus may not necessarily alter management be-
cause the risk of clinical embolization is thought to be
low [25]. However, left ventricular thrombus may be of
greater clinical importance in ICD patients as defibrilla-
tion threshold testing would generally be avoided [26].
Few patients underwent defibrillator threshold testing
in this cohort of patients and there were no thrombo-
embolic sequelae making the true clinical impact of
identifying thrombus unclear.
The clinical implication of this study is that the
technique used to measure EF in patients being con-
sidered for ICD therapy is relevant and may alter man-
agement. It is not known whether the use of CMR
will lead to improved clinical outcomes as CMR was
not used in the initial clinical trials of ICD therapy.
Nevertheless, the expense associated with ICD implant-
ation makes precise EF measurement for patient selec-
tion desirable [16]. Previous research has suggestedTable 4 ICD Eligibility at EF 30% Threshold
Echocardiographic EF
> = 30% < 30%
CMR EF >= 30% 32 0
< 30% 5 15
Kappa = 0.79.that if the echocardiographic EF is < 20%, no further
testing for EF is necessary, and our findings would
support this conclusion [17].
There are several limitations to this study. Import-
antly, this study assessed the potential rather than ac-
tual clinical impact of CMR. Echocardiographic reports
did not always quote a specific ejection fraction or
grade of left ventricular dysfunction that would allow
classification regarding ICD eligibility. Therefore, all
echocardiograms were re-read, as were the CMR stud-
ies, to obtain reproducibility data and verify the robust-
ness of the CMR ejection fraction measurements. A
similar proportion of patients were reclassified by CMR
when the original clinical CMR EF data were used. The
true clinical impact of CMR was difficult to ascertain due
to the variability in practice between treating physicians
and other factors, such as ICD implantation being guided
by a nuclear medicine EF despite CMR results. With
regard to thrombus detection, as there were no thrombo-
embolic sequalae and no repeat CMR scans (due partly
to ICD implantation) we do not have other supporting
evidence that the findings noted on CMR were indeedFigure 3 Gadolinium enhanced CMR viability image. a. Left
ventricular short axis mid-papillary orientation b. Apical 4 chamber
orientation. Mural thrombus with low signal intensity (arrow)
adjacent to blood pool and myocardial scar.
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for thrombus detection and the chronic nature of the left
ventricular dysfunction in this study makes the main dif-
ferential diagnosis, microvascular obstruction, unlikely
[12,13]. The findings of this study also may not be
generalizable to other centers given the variability in
echocardiographic, and to a less extent CMR, measure-
ment techniques. Neither contrast nor 3-dimensional
echocardiography were used, both of which have been
shown to increase the accuracy of EF assessment
[21,22,27,28]. Finally, as mentioned earlier, the lack of
outcome data leaves unanswered the question of whether
EF measurement by echocardiography or CMR has
greater prognostic significance.
Conclusion
In this cohort of patients being considered for ICD im-
plantation, CMR was substantially more reproducible
than echocardiography for EF and the agreement be-
tween techniques was only modest. Using strict EF cri-
teria, CMR would have resulted in almost 21% of
patients being reclassified regarding ICD eligibility, with
41% being reclassified if the echocardiographic EF was
between 25 and 40%. Left ventricular thrombus was also
uncovered by CMR in almost 10% of patients. CMR may
alter management in a substantial proportion of poten-
tial ICD candidates and should be strongly considered in
this patient group. Further trials of ICD therapy guided
by CMR findings are awaited.
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